Exercise therapy to enhance heart health in post-menopausal women after breast cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the impact of different amounts of aerobic exercise on cardiorespiratory fitness in post-menopausal women who have undergone treatment for early-stage breast cancer. Participants will engage in supervised aerobic training sessions, with their vital signs monitored to ensure safety. The research aims to determine how varying durations and intensities of exercise affect heart function, lung capacity, and overall cardiovascular health. The study will include assessments of how well participants' bodies utilize oxygen and how effectively their hearts pump blood.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Aged 21-80 years
* Female
* Surgically resected early stage (I-III) primary breast cancer
* Post-menopausal, defined as one of the following:

  * Age ≥ 45 with no menses for at least 2 years
  * Chemically and/or surgically induced menopause through ovarian suppression, as determined by the primary oncologist
  * Estradiol level of ≤30 pg/mL
* An interval of at least one year, but no more than five years, following the full completion of definitive therapy for malignant disease. Definitive therapy is defined as:

  * Surgery plus radiation
  * Surgery plus chemotherapy
  * Surgery plus trastuzumab
* Exercise intolerance (i.e., patients must have a VO2peak below the predicted for active age and sex-matched individuals. (+/- the technical error of 1.32 mL/kg/min)\].

Note: Normative values are available up to 80 years of age)

* Able to complete an acceptable baseline CPET, in the absence of high-risk ECG findings or other inappropriate response to exercise as determined by the PI, as defined by any of the following criteria:

  * Achieving a plateau in oxygen consumption, concurrent with an increase in power output;
  * A respiratory exchange ratio ≥ 1.10;
  * Attainment of maximal predicted heart rate (HRmax) (i.e., within 10 bpm of age-predicted HRmax \[HRmax = 220-Age\[years\]);
  * Volitional exhaustion, as measured by a rating of perceived exertion (RPE) ≥ 18 on the BORG scale
* Willingness to comply with all study-related procedures.

Exclusion Criteria:

* Any of the following absolute contraindications to cardiopulmonary exercise testing:

  * Acute myocardial infarction within 3-5 days of any planned study procedures
  * Unstable angina
  * Uncontrolled arrhythmia causing symptoms or hemodynamic compromise
  * Recurrent syncope
  * Active endocarditis
  * Acute myocarditis or pericarditis
  * Symptomatic severe aortic stenosis
  * Uncontrolled heart failure
  * Acute pulmonary embolus or pulmonary infarction within 3 months of any planned study procedures
  * Thrombosis of lower extremities
  * Suspected dissecting aneurysm
  * Uncontrolled asthma
  * Pulmonary edema
  * Respiratory failure
  * Acute non-cardiopulmonary disorders that may affect exercise performance or be aggravated by exercise (e.g., infection, renal failure, thyrotoxicosis)
* Presence of any other concurrent, actively treated malignancy
* History of any other malignancy treated within the past 3 years (other than non-melanoma skin cancer)
* Presence of distant metastatic disease (i.e., stage IV)
* Room air desaturation at rest ≤ 85%
* Mental impairment leading to inability to cooperate.
* Any other condition or intercurrent illness that, in the opinion of the investigator, makes the participant a poor candidate for the trial.

Where it's running

• Hartford Healthcare Cancer Institute @ Hartford Hospital (Data Collection Only)
  Hartford, Connecticut, United States Recruiting
• Memorial Sloan Kettering Cancer Center
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Jessica Scott, PhD — Memorial Sloan Kettering Cancer Center
• Study coordinator: Jessica Scott, PhD
• Email: scottj1@mskcc.org
• Phone: 646-888-8103

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• One-week versus three-week partial breast irradiation for early-stage breast cancer

  This trial tests whether a shorter one-week partial breast irradiation plan is not worse than a three-week plan for women after breast-conserving surgery.

  Recruiting Fudan University · Shanghai · NCT07832279

• Culmerciclib with endocrine therapy before surgery for early HER2-negative hormone receptor-positive breast cancer

  This trial tests whether adding culmerciclib to an aromatase inhibitor before surgery helps women with certain early breast cancers better shrink tumors than an aromatase inhibitor alone.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07796880

• Partial Breast Radiation After Breast-Conserving Surgery Without Sentinel Node Biopsy

  This pilot study tests whether partial breast irradiation is safe for women who had breast-conserving surgery without sentinel lymph node biopsy or axillary dissection.

  Recruiting NYU Langone Health · New York, New York · NCT07723209

• CDK4/6 inhibitors with endocrine therapy before surgery for HR+/HER2- high-risk early breast cancer

  This study tests whether adding a CDK4/6 inhibitor to endocrine therapy before surgery can help guide safer de-escalation of chemotherapy using ctDNA as a marker.

  Recruiting Phase 2 Peking University People's Hospital · Beijing, Beijing Municipality · NCT07366112

• Exercise and Quality of Life for Early-Stage Hormone Receptor–Positive/HER2-Negative Breast Cancer on Adjuvant Therapy

  This Spain-based trial tests whether a combined resistance and aerobic exercise program improves quality of life for women with early-stage HR+/HER2− breast cancer who are on adjuvant endocrine therapy, with or without a CDK4/6 inhibitor.

  Recruiting at 3 sites Spanish Breast Cancer Research Group · L'Hospitalet de Llobregat, Barcelona and 4 other locations · NCT07215364

• Using blood-based tumor DNA (ctDNA) to find leftover breast cancer after treatment

  This research will test whether a simple blood test that looks for tiny bits of tumor DNA can tell if people treated for breast cancer (including HR+/HER2-, HER2+, and triple-negative) still have leftover cancer or are at risk of recurrence.

  Recruiting at 16 sites Tempus AI · Birmingham, Alabama and 15 other locations · NCT07211178

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.